Reckitt Benckiser Group (LON:RKT) Announces Earnings Results

Reckitt Benckiser Group (LON:RKT) announced its quarterly earnings results on Thursday. The company reported GBX 349.70 ($4.52) earnings per share for the quarter, Digital Look Earnings reports. Reckitt Benckiser Group had a net margin of 10.78% and a return on equity of 18.70%.

Reckitt Benckiser Group Price Performance

Shares of RKT opened at GBX 5,418 ($70.03) on Friday. Reckitt Benckiser Group has a 1-year low of GBX 4,034 ($52.14) and a 1-year high of GBX 5,418 ($70.03). The stock has a market cap of £36.96 billion, a PE ratio of 24.79, a price-to-earnings-growth ratio of 1.10 and a beta of 0.09. The company has a debt-to-equity ratio of 110.26, a current ratio of 0.69 and a quick ratio of 0.46. The firm has a fifty day moving average price of GBX 5,116.55 and a 200 day moving average price of GBX 4,831.42.

Insider Activity at Reckitt Benckiser Group

In other Reckitt Benckiser Group news, insider Shannon Eisenhardt sold 1,368 shares of Reckitt Benckiser Group stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of GBX 4,723 ($61.04), for a total value of £64,610.64 ($83,508.65). 0.05% of the stock is owned by corporate insiders.

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.